1921
Volume 99, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Bolivian cutaneous leishmaniasis due to was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0183
2018-09-24
2019-11-18
Loading full text...

Full text loading...

/deliver/fulltext/14761645/99/5/tpmd180183.html?itemId=/content/journals/10.4269/ajtmh.18-0183&mimeType=html&fmt=ahah

References

  1. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, Carvalho E, Ephros M, Jeronimo S, Magill A, , 2017. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 96: 2445. [Google Scholar]
  2. Soto J, Paz D, Rivero D, Soto P, Quispe J, Toledo J, Berman J, , 2016. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 94: 852856. [Google Scholar]
  3. Soto J, 2013. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clin Infect Dis 56: 12551260. [Google Scholar]
  4. Miltefosine Product Label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204684s000lbl.pdf. Accessed August 27, 2018.
  5. Soto J, Buffet P, Grogl M, Berman J, , 1994. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 50: 107111. [Google Scholar]
  6. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A, Luz-Cjuno M, Echevarria J, Miranda-Verastegui C, Colina O, Berman JD, , 2005. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 72: 133137. [Google Scholar]
  7. Galvão EL, Rabello A, Cota GF, , 2017. Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis. PLoS One 12: e0186117. [Google Scholar]
  8. Soto J, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 12661272. [Google Scholar]
  9. Brahim LR, 2017. Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001–2013). Mem Inst Oswaldo Cruz 112: 838843. [Google Scholar]
  10. Brito G, Dourado M, Guimarães LH, Meireles E, Schriefer A, de Carvalho EM, Machado PRL, , 2017. Oral pentoxifylline associated with pentavalent antimony: a randomized trial for cutaneous leishmaniasis. Am J Trop Med Hyg 96: 11551159. [Google Scholar]
  11. National Institutes of Health, 1999. Common Toxicity Criteria (CTC). Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf. Accessed August 27, 2018.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0183
Loading
/content/journals/10.4269/ajtmh.18-0183
Loading

Data & Media loading...

  • Received : 02 Mar 2018
  • Accepted : 30 Jul 2018
  • Published online : 24 Sep 2018

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error